10.65
+9.01%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gossamer Bio
From its filings with the US Securities and Exchange Commission
Gossamer Bio is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GOSS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $48.5m and a net loss of $170.4m. At that date it held total assets of $172.2m and shareholders' equity of −$122.8m.
Our founders and management team have held senior positions at leading biopharmaceutical companies and possess substantial experience and expertise across the spectrum of drug development and commercialization.
Faheem Hasnain is our Co-Founder and has served as our Chief Executive Officer since November 2020 and as our Chairman since our inception. Mr. Hasnain also served as our Chief Executive Officer from our inception through July 2018 and our Executive Chairman from July 2018 through June 2019. Prior to co-founding Gossamer Bio, Mr. Hasnain served as President, CEO and as a Director of Receptos, Inc. from November 2010 to August 2015. Receptos was a public company formed in 2009 focused on developing treatments in immunology and metabolic disorders and was purchased by Celgene Corporation in August 2015. Previously, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company's acquisition by Abbott Laboratories in April 2010.
Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Feb 2019
- Employees
- 161
- Website
- gossamerbio.com ↗
- Head office
- 3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Faheem HasnainChairman of the Board, President, Chief Executive Officer, Co-Founder, since 2018$2.0m
- Mr. Bryan GiraudoChief Operating Officer, Chief Financial Officer$1.2m
- Ms. Caryn PetersonExecutive Vice President - Regulatory Affairs
- Mr. Christian WaageExecutive Vice President - Technical Operations and Administration$1.7m
- Dr. Richard ArandaChief Medical Officer$1.1m
- Mr. Robert SmithChief Commercial Officer$1.3m
- Dr. Thomas DanielLead Independent Director$128,465
- Mr. Russell CoxIndependent Director$114,965
- Dr. Skye DrynanIndependent Director$290,415
- Dr. Sandra MilliganIndependent Director$109,465
- Dr. Steven NathanIndependent Director$284,915
- Dr. John QuiselIndependent Director$102,965
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 50
- Environment
- 51
- Social
- 69
- Governance
- 29
- Women in the workforce
- 55%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gossamer Bio Inc has several strengths that give it a competitive advantage in the market. These include:
- Gossamer Bio Inc boasts a diverse and innovative product portfolio that caters to various medical needs. This allows the company to target multiple market segments and increase its revenue potential.
- The company is led by a highly skilled and experienced management team with a proven track record in the pharmaceutical industry. Their expertise contributes to effective decision-making and strategic planning.
Weaknesses
- Despite its strengths, Gossamer Bio Inc also faces certain weaknesses that it needs to address in order to improve its market position:
- Compared to some of its competitors, Gossamer Bio Inc has a relatively limited market presence. This can hinder its ability to reach a larger customer base and compete effectively in certain markets.
- Developing and conducting extensive research for new medical products can be costly for Gossamer Bio Inc. This may put pressure on its financial resources and limit its ability to invest in other areas of the business.
Opportunities
- Gossamer Bio Inc can leverage the following opportunities to expand its market share and achieve business growth:
- Expanding into emerging markets presents an opportunity for Gossamer Bio Inc to tap into new customer bases and increase its revenue streams. These markets often have growing demand for healthcare products.
- Rapid advancements in technology present opportunities for Gossamer Bio Inc to develop innovative solutions and improve existing products. This can enhance the company's competitiveness and attract more customers.
Threats
- Gossamer Bio Inc should also be aware of potential threats in the market that could hinder its growth:
- The pharmaceutical industry is highly competitive, with numerous companies vying for market share. Gossamer Bio Inc must continually innovate and differentiate itself to stay ahead of competitors.
- The pharmaceutical industry is subject to strict regulations and compliance requirements. Gossamer Bio Inc must ensure that its products meet all necessary regulations, which can be time-consuming and costly.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.